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A 59-year-old smoker consulted for a pulmonary nodule.Computed tomography (CT) scan lung biopsy diagnosed
a non-small cell lung cancer (NSCLC) of adenocarcinoma
subtype. Positron emission tomography demonstrated a left
adrenal metastasis. First-line chemotherapy with a combina-
tion of pemetrexed and carboplatin was performed. After four
cycles, a partial response was observed according to RECIST
1.1 criteria. During the same period, epidermal growth factor
receptor (EGFR) mutations were characterized according to a
sensitive method based on high-performance liquid chroma-
tography and sequencing (Figures 1A, B). The rare mutation
A859T was observed. Erlotinib was introduced after a wash-out
period of 4 weeks. Tolerance was excellent. Eight weeks later,
CT scan demonstrated a partial response (criteria RECIST 1.1
 41%). Maximal standard uptakes of 18F-fluorodeoxyglucose
(FDG) showed a reduction for primary and secondary tumors,
3.9 to 1.0 and 2.9 to 2.3, respectively (Figure 2). The radio-
graphic response was confirmed with a CT scan 3 months later.
To date, the duration of response is 3 months.
Activating EGFR mutations are predictive responses
for the tyrosine kinase inhibitors (TKIs) gefitinib and erlo-
tinib. The most frequent deletions and mutations, located in
exon 19 and 21, are observed from 10% in Caucasian popu-
lations1 up to 40 to 60% in female, nonsmoking Asian
populations.2 Alongside the most frequent activating EGFR
mutations, many other less frequent mutations have been
described.3 In general, little is known about the sensitivity or
the lack of sensitivity to TKIs in humans.
A859T EGFR mutation has already been reported twice
and has been associated with the absence of sensitivity to
gefitinib.4,5 Functional analysis of A859T EGFR mutation
exposed to erlotinib based on a cellular assay concluded that
this variant could be a silent polymorphism.6 To the contrary
of all these published data, our case supports the evidence of
a therapeutic effect of erlotinib in a NSCLC patient bearing
A859T EGFR mutation. The proofs are a tumor size reduc-
tion and a decrease of the FDG maximal uptake after 8 weeks
of treatment and confirmed 3 months later. Although the
follow-up of our case is limited, our observation seems
similar to patients with TKI-sensitive adenocarcinomas har-
boring a frequent EGFR mutation: significant shrinking
tumor size after TKI introduction, long period of stable
disease, and good tolerance. For all the reasons, we con-
sider that A859T EGFR mutation could be an activating
mutation-associated response to erlotinib. Because of the
lack of a reliable tool to predict EGFR mutation sensitivity
of current TKIs, we recommend that physicians test both/
several TKIs for every NSCLC patient harboring a rare/
new EGFR mutation.
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FIGURE 1. Genomic DNA was isolated from
paraffin-embedded tumor samples. EGFR gene
exons 18, 19, 20, and 21 were each amplified by
polymerase chain reactions, and the products
were screened for mutations by denaturing high-
performance liquid chromatography (A). An addi-
tional peak in the exon 21 amplicon was observed
and direct sequencing revealed mutation
p.Arg859Asp (B).
FIGURE 2. Computed tomography and positron emission tomography scans and fused images before and 8 weeks after
erlotinib.
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